MobiHealth News February 16, 2022
The company’s REMI product is currently FDA cleared for in-hospital use, but Epitel plans to expand into ambulatory and in-home care.
Epitel, maker of a wearable electroencephalogram (EEG) system for seizure detection, announced Wednesday it had scored $12.5 million in Series A funding.
The round was led by Catalyst Health Ventures (CHV) and Genoa Ventures, with participation from Dexcom, OSF Ventures, Wavemaker 360, MedMountain Ventures and Salt Lake City Angels.
Before the Series A, Epitel had brought in more than $7.5 million, largely from grant funding.
WHAT IT DOES
The company’s first product, the REMI system, consists of a wearable, wireless EEG sensor that’s applied below the hairline, and software for providers to review data and monitor for seizures....
Today's Sponsors
Today's Sponsor